Black Diamond Therapeutics, Inc. (BDTX)
1.78
-0.08
(-4.30%)
USD |
NASDAQ |
Oct 30, 16:00
1.77
-0.01
(-0.56%)
After-Hours: 20:00
Black Diamond Therapeutics Debt to Equity Ratio : 0.1766 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.1766 |
| March 31, 2026 | 0.1714 |
| December 31, 2025 | 0.1674 |
| September 30, 2025 | 0.1559 |
| June 30, 2025 | 0.1565 |
| March 31, 2025 | 0.1525 |
| December 31, 2024 | 0.2664 |
| September 30, 2024 | 0.2361 |
| June 30, 2024 | 0.2142 |
| March 31, 2024 | 0.2353 |
| December 31, 2023 | 0.2167 |
| September 30, 2023 | 0.1939 |
| June 30, 2023 | 0.3255 |
| March 31, 2023 | 0.2796 |
| December 31, 2022 | 0.2432 |
| September 30, 2022 | 0.2163 |
| Date | Value |
|---|---|
| June 30, 2022 | 0.1893 |
| March 31, 2022 | 0.1637 |
| December 31, 2021 | 0.1453 |
| September 30, 2021 | 0.1316 |
| June 30, 2021 | 0.0552 |
| March 31, 2021 | 0.0507 |
| December 31, 2020 | 0.0284 |
| September 30, 2020 | 0.0265 |
| June 30, 2020 | 0.0012 |
| March 31, 2020 | 0.0012 |
| December 31, 2019 | -4.253 |
| September 30, 2019 | -2.911 |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | -3.910 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Lineage Cell Therapeutics, Inc. | 0.0377 |
| Armata Pharmaceuticals, Inc. | -1.358 |
| Voyager Therapeutics, Inc. | 0.211 |
| Invivyd, Inc. | 0.0463 |
| Elicio Therapeutics, Inc. | 1.782 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 125.03M |
| Total Liabilities (Quarterly) | 28.94M |
| Shareholders Equity (Quarterly) | 96.09M |
| Current Ratio | 7.284 |
| Net Debt Paydown Yield | 0.87% |